as 08-08-2025 4:00pm EST
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Founded: | 2012 | Country: | Ireland |
Employees: | N/A | City: | DUBLIN 2 |
Market Cap: | 366.6M | IPO Year: | N/A |
Target Price: | $24.29 | AVG Volume (30 days): | 955.8K |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.63 | EPS Growth: | N/A |
52 Week Low/High: | $4.32 - $23.66 | Next Earning Date: | 08-04-2025 |
Revenue: | $10,341,000 | Revenue Growth: | -95.24% |
Revenue Growth (this year): | -75.92% | Revenue Growth (next year): | 122.46% |
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
BioPharma Dive
2 months ago
Business Wire
2 months ago
Insider Monkey
2 months ago
TipRanks
2 months ago
BioPharma Dive
2 months ago
Zacks
2 months ago
MT Newswires
2 months ago
Business Wire
2 months ago
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.